This could be useful as a stratification parameter in trials with new drugs in a metastatic setting. In the multivariate setting, the adjusted hazard ratio (HR) was 1.39 (95% CI = 1.03-1.89 P = 0.04), stratified by chemotherapy regimen.Ī short PSA-DT before onset of chemotherapy in HRPC patients was associated with an increased risk of death. The median survival was 16.5 months (95% confidence interval = 12.5-20.5) and 26.4 months (95% CI = 20.3-32.4) for patients with a PSA-DT or =45 days, respectively. The median PSA-DT was 45 days (range 4.7-1108 days). There was significant difference found of initial PSA level between survivor (445,7 + 165,6 ng/mL) and non-survivor (200.7 + 144.9 ng/mL). A total of 24 patients with CRPC were evaluated in this study. Patients received docetaxel- (82%) or mitoxantrone-based chemotherapy. Evaluation data included sex, age, initial PSA level, final PSA level, time to PSA nadir (TTN), time to CRPC progression (TTC), and survival status. Multivariate Cox regression analysis was performed to isolate the impact of PSA-DT on OS, controlling for associate prognostic covariates. Survival rates according to PSA-DT were stratified on chemotherapy regimen. The primary endpoint was overall survival (OS). PSA (prostate-specific antigen) doubling time. PSA-DT was calculated as ln 2 divided by the slope of the log PSA line, and the difference between two log PSA levels was divided by the time interval. treatment, whereas those with more rapidly progressive cancer would still benefit from curative therapy.

At least three PSA assays were required within 3 months before chemotherapy.

I was looking for this particular information for a long time. PSA velocity or PSA doubling time, both of which measure the rate at which your PSA. As soon as one treatment comes out others will follow not far behind, Purchase proscar. We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients.ĭata from 250 consecutive metastatic HRPC patients treated with chemotherapy between February 2000 and November 2006 were retrospectively analysed. If the hormone therapy stops working, what treatment options remain.

Psa doubling time survival rate